Navigation Links
Securian's Minnesota Life Continues to Climb Group Life Rankings
Date:9/6/2007

ST. PAUL, Minn., Sept. 6 /PRNewswire/ -- Minnesota Life Group Insurance has grown from the nation's sixteenth largest group life insurer to the fifth largest in only ten years.

According to data published by A.M. Best, Minnesota Life's group life insurance in force rose from $81 billion in 1996 to $475 billion 2006 and now tops $500 billion.

"Our service sets us apart," said Jim Johnson, executive vice president, Securian Financial Group (http://www.securian.com) and head of the group life business unit. "We've found that high-touch service combined with high-tech accessibility is the combination our clients are looking for." Respondents to customer surveys are 100 per cent satisfied with the service they receive from Minnesota Life, giving the company the exceptional Net Promoter(R) Score of 87 percent.

Minnesota Life's target market in the private sector is Fortune 1000 employers. In the public sector, the company provides group life benefits to nine state government employee groups, with the tenth and eleventh coming on board January 1, 2008.

Minnesota Life was among the first to enter the group life business, writing its first policy 90 years ago in 1917. In 1999, it was among the first to offer web-based group life administration for employers and employees.

For more information about web-based services offered by Minnesota Life Group Insurance, visit http://www.lifebenefits.com.


'/>"/>
SOURCE Securian Financial Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Blue Cross Signs Up 110,000 Minnesotans For Part D Medicare Plans
2. OxyContin Abuse Continues To Rise
3. Alzheimer’s Continues to Ris
4. Uttar Pradesh Encephalitis toll continues to rise - Over 600 dead
5. Human Brain Continues To Evolve And Grow
6. War Against Cancer Continues
7. Botswana Continues Its Fight Against AIDS
8. US Continues Its War On Diabetes
9. Polio Continues To Haunt India
10. Patients Left Helpless As Mumbai Doctors Strike Continues
11. Health Services Came To A Halt As Mumbai Doctors Strike Continues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...ert Pathologists Discuss the Latest Developments i...RTHFIELD, Ill., Sept. 5 /PRNewswire-USNewswire/ --...point. Molecular testing and the promise,of person...reated. Digital,slides and other imaging technolog...lege of American Pathologists is taking a leadersh...
(Date:9/5/2008)...hers explain how theoretical ,anti-cloak, could br...pt. 5 (HealthDay News) -- Just in case someone dev...cientists say they know how to uncloak the objects... Optics Express , certain materials underneath an ...o be seen again. , Researchers at Shanghai Jiao...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- Speake...y in support of the aims of the "Stand,Up to Cance... "There is not a person in our country who has no...r kills 565,000 Americans annually, and each,year ...ricans must work,together to make eradicating the ...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- U.S. c...r relief to Cuban victims of Hurricane,Gustav, whi...s., (http://www.PanAmericanRelief.org ), "Donatio...perately need,after this natural disaster," says M... Initiative at the Pan American Development Founda...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2
...industrialised nations summit, which begins on Sat...obal health issues high on its list// of priority....h officer, addressing the press stated that the G8...hat would establish the basic guidelines for comba...
...ds Agency (FSA) has said that one in five take-out...ews for over 1.3 million Britons// who thrive on t...oncern since many fast-food restaurants were found...properly before packing the food. Also infestation...
...k, all of two years, found his eyelids stuck toget...his eye, instead of using it to treat a head// inj...ye Infirmary where he was administered treatment. ...some improvement, though a major portion of the ey...
... about the inherent risks involved in the consumpt...e human milk is capable of causing food poisoning ...ces that the human milk carries remnants of drugs ...when consumed. Even unhygienic storage of milk, an...
Other Medicine News:
(Date:9/4/2008)...ouncements Remain on Schedule with Two Abstracts A...ata Release in November 2008, BRIDGEWATER, N.J., ...Inc., a specialty pharmaceutical company focused o...sease, today announced the appointment of,Peter L....rs., Peter Garrambone,s career includes more than...
(Date:9/3/2008)..., China, Sept. 3 /- Simcere...ufacturer and supplier of,branded generic pharmace...er biotech product Endu (also known as Endostar) i...se IV clinical study., At the request of the SFDA...urther validate the safety and therapeutic efficac...
(Date:9/3/2008)...September is National Vascular Disease Awareness M...-- Diffusion Pharmaceuticals,LLC, a clinical-stage...s,for the treatment of unmet medical needs, announ...a Phase I/II clinical trial of its lead drug,candi...signated NCT00725881,on the clinicaltrials.gov Web...
(Date:9/3/2008)...ysis showed that Multaq(R) (dronedarone) decreased...fibrillation or atrial flutter already ...RIDGEWATER, N.J., Sept. 3 /...rom the ATHENA study were presented today at,the c...ty of Cardiology,congress 2008, in Munich, Germany...
Breaking Medicine Technology:Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5The HealthCentral Network Adds Skin Care Site to Its Web Properties 7104 1The HealthCentral Network Adds Skin Care Site to Its Web Properties 7104 2NanoLogix Inc Files Multiple International Patent Applications for BioNanoChannel 28TM 29 and Hydrogen Bioreactor Technology 7100 1NanoLogix Inc Files Multiple International Patent Applications for BioNanoChannel 28TM 29 and Hydrogen Bioreactor Technology 7100 2MetaCure 28TM 29 Launches Investigational Study of Gastric Stimulator for Patients With Type 2 Diabetes Who are Overweight 7096 1MetaCure 28TM 29 Launches Investigational Study of Gastric Stimulator for Patients With Type 2 Diabetes Who are Overweight 7096 2Pneumococcal conjugate vaccines can improve the lives of HIV infected children 7092 1Pneumococcal conjugate vaccines can improve the lives of HIV infected children 7092 2
... March 27, 2007--A new study shows that as rates,o...of,cardiovascular disease (CVD) linked to diabetes...e need for increased efforts to,prevent diabetes a...ors among those with diabetes, according to the in...t Study, a program of the,National Heart, Lung, an...
...sults for the year ended 31 December 2006 , Produc...e Phase,III study International partnering process..., March 28, 2007 - CeNeS Pharmaceuticals,plc ("CeN...specialty pharmaceutical company, today announces ...mber 2006. , Operational Highlights , Clinical pip...
Other Medicine Technology:Increasing Proportion of Cardiovascular Disease Due to Diabetes,Over the Last 50 Years 2Increasing Proportion of Cardiovascular Disease Due to Diabetes,Over the Last 50 Years 3CeNeS Pharmaceuticals Plc Announces Preliminary Results for The,Year Ending 31 December 2006 2CeNeS Pharmaceuticals Plc Announces Preliminary Results for The,Year Ending 31 December 2006 3
Used as a percutaneous entry needle to introduce wire guides. The coaxial design reduces potential A.V. malformations. Supplied sterile in peel-open packages. Intended for one-time use.
Used for stone manipulation and removal in the urinary tract. Enhanced wire strength permits the basket to expand the ureter more readily than standard flat-wire designs. The Unidex handle facilitate
...d for stone manipulation and removal in the urinar... to retain its shape following extreme torsion. Th...ture by allowing the basket to open at the base of...ign reduces the likelihood of mucosal damage and p...
Used to establish and maintain nephrostomy drainage following pyeloplasty. Supplied sterile in peel-open packages. Intended for one-time use. CAUTION: Periodic evaluation is advised; stent must not r
Medicine Products: